Ross, Leila SaxbyLafuente-Monasterio, Maria JoséSakata-Kato, TomoyoMandt, Rebecca E. K.Gamo, Francisco JavierWirth, DyannLukens, Amanda2018-05-302018Ross, Leila Saxby, Maria José Lafuente-Monasterio, Tomoyo Sakata-Kato, Rebecca E. K. Mandt, Francisco Javier Gamo, Dyann F. Wirth, and Amanda K. Lukens. 2018. “Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.” ACS Infectious Diseases 4 (4): 508-515. doi:10.1021/acsinfecdis.7b00217. http://dx.doi.org/10.1021/acsinfecdis.7b00217.http://nrs.harvard.edu/urn-3:HUL.InstRepos:37068218Drug resistance has been reported for every antimalarial in use highlighting the need for new strategies to protect the efficacy of therapeutics in development. We have previously shown that resistance can be suppressed with a population biology trap: by identifying situations where resistance to one compound confers hypersensitivity to another (collateral sensitivity), we can design combination therapies that not only kill the parasite but also guide its evolution away from resistance. We applied this concept to the Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) enzyme, a well validated antimalarial target with inhibitors in the development pipeline. Here, we report a high-throughput screen to identify compounds specifically active against PfDHODH resistant mutants. We additionally perform extensive cross-resistance profiling allowing us to identify compound pairs demonstrating the potential for mutually incompatible resistance. These combinations represent promising starting points for exploiting collateral sensitivity to extend the useful lifespan of new antimalarial therapeutics.en-USDHODHmalariacollateral sensitivitydrug resistancedrug combinationsJournal Article2018-05-3010.1021/acsinfecdis.7b00217